

# Index

Note: page numbers followed by f refer to figures, those followed by t refer to tables.

- AAI pacemakers, 95
- ablation/ablative techniques
  - atrial fibrillation, 236–9
  - atrial flutter, 233–6
  - atrioventricular (AV)
    - junction, 213–4
  - AV nodal reentrant
    - tachycardia, 214–20, 215f, 217f, 218f, 219f
  - bypass tracts (*See* bypass tract ablation)
  - His bundle, 214, 220, 232, 307
  - radiofrequency (*See* radiofrequency ablation)
  - radiofrequency vs. direct current (DC) shock, 211
  - sinoatrial (SA) node, 149
  - transcatheter, *See* transcatheter ablation
  - ventricular tachycardia
    - idiopathic, 195, 247–8
    - reentrant, 239–47, 241f, 243f, 244f, 245f
- N*-acetylprocainamide, 26, 26t, 27
- action potential, 5–9, 6f, 8f
- antiarrhythmic drug effects, 5
  - depolarization (*See* depolarization)
  - localized differences, 9–11
  - repolarization, 7
  - resting phase, 8–9
  - surface ECG relationship, 10f, 11–12
- activation mapping, 233, 240–42, 244f, 245, 247, 248
- A deflection, 49f, 51, 52, 79, 82
- adenosine, 158, 171, 172, 228, 231
- $\beta$ -Adrenergic tone, 280
- AFFIRM trial, 154, 155
- afterdepolarizations, 21, 91f, 192f
  - delayed, 193
  - early, 190, 191
  - triggered activity ventricular arrhythmias, 194f
- AH interval, 52, 80, 81f, 82f, 83, 84, 86–8, 91f, 114, 125f, 127f, 137f, 146
- first-degree AV block, 14, 73, 74f, 78t, 80, 81f, 275, 303t
- prolongation in second-degree AV block, 14
- ambulatory monitoring, 277, 283, 284, 301, 302, 307
- American College of Cardiology, 265
- American Heart Association, 265
- American Society of Echocardiography, 270
- amiodarone, 26t, 27, 30t, 31, 31t, 32, 143, 189, 199, 200, 201t, 202, 204t, 205
- anatomy
  - AV node, 3–4
  - cardiac electrical system, 4
  - SA node, 4

- anteroseptal bypass tracts, 231  
 ablation, 232
- antiarrhythmic drugs. *See also specific drugs*
- automatic tachycardia  
 induction, 17
- class I, 26t  
 action potential effects, 25f, 26t  
 effect on rapid sodium channel, 24f  
 mechanism of action, 23–4
- class Ia, 25  
 atrial fibrillation, 145f, 152, 153  
 atrial flutter, 151  
 AV nodal bypass tracts, 146  
 AV nodal reentry, 130  
 contraindications, 45  
 intraatrial reentry, 107  
 macroreentrant supraventricular tachycardia, 141  
 proarrhythmia risk, 29, 30t  
 reentrant supraventricular tachycardia, 105
- class Ib, 26t  
 contraindications, 27  
 effect of, 27  
 proarrhythmia risk, 29  
 reentrant supraventricular tachycardia, 105, 106f, 149  
 reentrant tachycardias, 56, 58  
 side effects, 31t
- class Ic, 26t  
 atrial fibrillation, 152  
 atrial flutter, 151  
 AV nodal bypass tracts, 146  
 AV nodal reentry, 130  
 inappropriate sinus tachycardia, 71, 104  
 intraatrial reentry, 118, 148–9  
 macroreentrant supraventricular tachycardia, 143  
 proarrhythmia risk, 30t  
 reentrant supraventricular tachycardia, 105, 106f, 121, 134–5, 149
- classification, 24–7, 26t  
 class II, 27, 201  
 class III  
 action potential effects, 27  
 atrial fibrillation, 107–8  
 atrial flutter, 107–8  
 intraatrial reentry, 108  
 proarrhythmia risk, 30t  
 class IV, 26t, 27  
 class V, 26t  
 effect of, 27–9  
 on reentrant circuit, 28f  
 mechanisms of action, 23–4, 24f  
 proarrhythmic effect, 199  
 reentrant arrhythmias, 29, 30, 109  
 reentrant ventricular arrhythmias, 59, 162–4, 166, 189  
 side effects, 31t  
 toxicity, 30–32
- antitachycardia pacing (ATP), 187
- anxiety, 44, 45, 287, 293–5
- arrhythmias. *See also specific types*
- ambulatory monitoring, 277, 283, 284, 301, 302, 307
- benign, 307
- cause symptoms, 304
- diagnosis, 58, 109, 279
- exacerbation  
 (proarrhythmia), 29–30
- moderate-risk, 306
- sudden death risk,  
 classification, 166t, 303t
- symptoms  
 severity classification, 14
- three step evaluation/treatment plan, 282, 299
- treatment  
 ablation, *See* ablation/ablative techniques  
 device therapy, 32–3  
 nonpharmacologic, 32  
 pharmacologic,  
*See* antiarrhythmic drugs  
 plan design, 300, 306

- surgical, 32
  - therapeutic endpoints, 300
  - underlying cause reversal, 27, 32
- arrhythmic symptoms
  - high-risk, 305
  - severity classification, 305t
- A spike, 51, 52, 83, 125
- atrial defibrillation, 153
- atrial fib-flutter, 150
- atrial fibrillation, 145f, 152, 153, 276, 306, 307
  - brady-tachy syndrome, 61–3
  - bypass tracts, 144–6
  - chronic, 63, 100, 150
  - diagnosis, 156
  - electrophysiology study, 149, 152
  - functional refractory period, 54, 84, 174
  - paroxysmal/recent onset, 155
  - patient with an AV bypass tract, 145f
- P waves, 108f
- supraventricular tachycardias
  - reentrant, 105–9
- treatment
  - ablative, 153, 154, 236–9, 251
  - AFFIRM and RACE clinical trial, 154–6
  - pacemakers, 154
  - rate control, 154
  - rhythm control, 152–4
- atrial flutter
  - electrophysiology study, 149–51
  - treatment, 151
  - types, 151f
- atrial myocardium, 103, 106f, 107, 117, 132, 148, 149, 152
- atrial pacing, 47, 48, 88, 97, 148, 150, 228
- atrial tachycardia, 98, 103
  - ablation of, 233
  - multifocal, 104
  - paroxysmal, 105, 171
  - reentrant, 107
- atrial thrombi, 152, 153
- atrioventricular (AV) block, 13, 14, 72–84, 76f, 88, 91, 91f, 93, 101, 103, 105, 107, 108, 115, 148, 158, 172, 275, 303t
  - automatic atrial tachycardia, 17, 103, 105, 107, 108, 148
  - classification of, 14, 14f, 74–6
  - complete, 14, 73, 76f, 77, 78, 213, 220, 232, 257, 303
  - distal, 15, 73, 76, 83f, 84, 91f
  - first-degree, 14, 73
    - His bundle electrogram of, 74
  - intermittent, 14, 74, 79f
  - localizing, 78–9, 79f
  - second-degree, 74
    - His bundle electrogram of, 75f
    - localization, 74
    - type II *See* Mobitz type II block
    - type I *See* Mobitz type I block (Wenckebach block)
  - syncope, 72, 73, 275
  - third-degree, 14f, 76
    - His bundle electrogram, 77f
  - treatment, 77–8
- atrioventricular (AV) bypass tracts, 20, 32, 115, 117f, 131, 132, 135, 143, 145, 250
- atrioventricular (AV) conduction, 47, 52, 62, 72, 79, 80, 92, 101, 127, 134, 136, 140f, 152, 154, 274
- atrioventricular (AV) dissociation, 77f, 172t, 248
- atrioventricular (AV) groove, 3–4
- atrioventricular (AV) interval, 97f, 99f, 139, 223, 224, 269
- atrioventricular (AV) junction, ablation, 213–4
- atrioventricular (AV) nodal reentrant tachycardia, 106f, 118, 121, 122, 123, 127, 214, 216, 220, 231
  - activation patterns, 127–8

- atrioventricular (AV) nodal reentrant tachycardia, (*Continued*)
- atrial/ventricular myocardium involvement, 128
- atypical, 129
- electrophysiology study, 121–2
- initiation, 124, 125f, 126f
- mechanism of reentry, 122–3, 122f
- P wave, 141
- QRS complex, 135f, 137f, 141
- supraventricular, 130–4
- termination, 124
- treatment, 130
- atrioventricular (AV) node
- action potential, 10
- anatomy and physiology, 123, 215f
- autonomic innervation, 11, 15, 78, 118
- bypass tracts of, 134
- conduction (*See* atrioventricular (AV) conduction)
- depolarization, 79
- effective refractory period, 84
- automaticity, 8f, 11, 50–51
- abnormal, 189
- autonomic innervation influence, 11
- electrophysiologic evaluation, 50
- programmed stimulation, 41, 53
- SA node assessment, 13
- SA node insufficiency, 13, 63
- tachycardias (*See* tachycardias, automatic)
- automatic supraventricular tachyarrhythmias, 103–5, 104f
- autonomic blockade, 70, 71
- autonomic maneuvers
- AV block localization, 78
- AV nodal reentry, 106
- reentrant arrhythmias, 58
- supraventricular tachycardias, 111
- autonomic nervous system automaticity influence, 70
- dysautonomia, 287, 295
- localized differences, 61
- SA node, 61
- autonomic tone, 55, 58, 61, 70, 297
- AV conduction disorders
- evaluation, 72
- electrophysiology study, 79–88
- site of, 72
- AV nodal block, 72–3
- His–Purkinje block, 73
- symptoms of, 72
- AV See entries beginning atrioventricular*
- baseline recording, 47, 49f, 110f
- Baye’s theorem, 179
- $\beta$ -blocking drugs, 26t, 27, 31t, 58, 71, 79t, 106, 123, 145, 154, 196, 198, 281, 294, 297, 307
- bilateral fascicular block, 93
- bipolar recording configuration, 40
- biventricular pacing, 99, 259, 260, 261f, 264t, 265, 269. *See also* cardiac resynchronization therapy (CRT)
- bradyarrhythmias, 13, 32, 304. *See also* cardiac arrhythmias
- impulse generation, 13
- impulse propagation, 13–15
- sinus, 61, 71, 72
- syncope, 275
- bradycardia, 279
- prolonged, 282
- sinus, 14f, 62, 71
- sudden, 170
- brady-tachy syndrome, 62
- brain scanning, 283
- bretylum, 31t
- Brugada syndrome, 197, 277
- bundle branch block, 260
- left, 92–3
- reentrant supraventricular tachycardia, 118
- right, 91–2
- surface ECG effects, 89f, 90

- ventricular dyssynchrony and, 91, 92
- bundle branch reentry, 163t, 196, 248–50, 249f
- burst pacing. *See* incremental (burst) pacing
- bypass tract ablation
  - anteroseptal, 231, 232f
  - characteristics, 220–1
  - left free wall, 221, 221f, 222f, 226
  - midseptal, 221, 222t, 232, 232f
  - paraseptal, 221, 229, 230
  - posterior septal, 144, 221, 223, 229, 230, 232
  - right free wall, 226–7
- bypass tracts
  - ablation (*See* bypass tract ablation)
  - antegrade conduction, 133, 139
  - anterior septal, 140
  - anteroseptal and midseptal, 231–2
  - atrial fibrillation and, 120, 144–6, 145f
  - atrial flutter and, 134, 144–6
  - atrioventricular/AV nodal, 301
  - AV nodal bypass tracts, 146
  - characteristics of, 131, 146, 220–1
  - concealed, 106, 133, 134, 136, 138f, 139, 144
  - fasciculoventricular, 147
  - localization, 143–4
    - approaches according to, 226–32
  - localization/mapping
    - ECG, 221f, 222t
  - Mahaim, 146–7, 227–9
  - mediated macroreentry, 134, 135f
    - atria and ventricles in
      - macroreentry, requirement of, 140–1
    - electrophysiology study, 134
    - induction, 137f
    - initiation and
      - termination, 135–6, 138f
    - macroreentrant
      - supraventricular
        - tachycardia, 130–5
        - macroreentrant
          - tachycardia, 106–7, 106f
      - patterns of atrial and
        - ventricular activation, 139–40
      - multiple, 147
      - posterior septal (and
        - paraseptal), 229–30
      - potential, 225f
      - retrograde activation, 117f, 120, 140, 147
      - supraventricular tachycardia (*See under* supraventricular tachycardias)
      - surgical treatment, 147–8
  - calcium-channel blockers, 22, 26t, 27, 195, 196
    - AV nodal reentry, 26t, 27
    - idiopathic left ventricular tachycardia, 195
    - SA nodal reentry, 26t, 27
    - triggered activity tachycardias, 22
    - ventricular arrhythmias, 195
  - calcium channels, 7, 22, 27
  - cardiac action potential *See* action potential
  - cardiac arrhythmias, 273, 305, 309
    - management of, 299, 300, 306
    - severity of, 301
    - treatment of, 299
  - cardiac arrhythmias, treatment
    - steps, 299
    - arrhythmia severity, assess, 300–302
      - arrhythmia, diagnosing, 302–3
      - arrhythmia, symptom, 303–5
      - heart disease, 305
    - therapeutic end point, 305–6
    - treatment plan, design, 306
      - to prevent sudden death, 308
      - to relieve symptoms, 307–8
  - cardiac arrhythmia suppression trial (CAST), 199
  - cardiac catheterization, 302

- cardiac cells, 5
- cardiac C fibers, 278–9, 281–2
- cardiac electrical system, 3, 51
- cardiac emergency equipment, 43
- cardiac event recorder, 284, 290, 302
- cardiac ischemia, 17, 32, 44, 193, 302
- cardiac loop recorder, 284
- cardiac monitoring, SA node dysfunction
- cardiac MRI, 270
- cardiac perforation, radiofrequency ablation risk, 257
- cardiac resynchronization therapy (CRT), 92, 258
  - biventricular pacing, 259
  - clinical studies, 262
    - mild to moderate heart failure, 264–5
    - moderate to severe heart failure, 262–4
  - effects of, 261
    - contractility, 261–2
    - hemodynamic effects, 261
    - reverse remodeling, 262
  - implanting devices, 266–7
  - indications for, 265–6
  - optimization of, 268
    - AV interval, 269
    - lead placement/lead number, 270
    - measuring dyssynchrony, 270–1
    - VV interval, 269
  - pacemakers, 259
  - randomization, 263t–264t
  - unresolved issues
    - responders vs. nonresponders, 267–8
  - works process, 259–61
- cardiac-rhythm disturbances
  - management of, 299
- cardiac tamponade, radiofrequency ablation risk, 230
- cardiomyopathy, 170, 172, 196, 201, 207, 241, 260f, 274t, 284, 307
- cardioneurogenic syncope, 93, 278
- cardioneurogenic syncope *See* vasodepressor syncope
- CARE-HF trial, 264t, 268
- CARTO mapping system, 251–3
- CAST trial, 199
- catecholaminergic polymorphic ventricular tachycardia, 197–8
- catechol-dependent triggered activity
  - ventricular tachycardias, 163t, 191f, 193, 195
- catheterization laboratory, 42, 45
- catheterization, risks of, 59
- chronic AV pacing, 271
- chronic fatigue syndrome (CFS), 287
- chronic lyme disease, 287
- COMPANION trial, 263
- concealed conduction, 136, 138
- conduction, AV node. *See* atrioventricular (AV) conduction
- conduction interval, 48, 49f, 51, 52, 114
  - retrograde, 115
- conduction velocity, 51–2, 55
- congestive heart failure, 205, 261, 304, 305t, 307
- consciousness loss *See* syncope
- coronary bypass surgery, 32
- coronary sinus, 266, 267
- corrected sinus node recovery time (CSNRT), 66, 67
- coupling interval, 38
- crista terminalis, 61, 233, 234f, 235, 293
- CRT. *See* cardiac resynchronization therapy (CRT)
- CRT, effects of, 261
- CRT pacemakers, 259, 272
- CRT pacing, 272
  - NYHA class II/III heart failure, 272

- CRT therapy, 266, 267  
 cryoenergy, 213  
 cycle length, 37–8
- DAVID trial, 271
- DC cardioversion. *See* direct current (DC) cardioversion
- DC shock *See* direct current (DC) shock
- DDD pacemakers, 97f, 98, 99f, 259
- DDDR pacemakers, 101
- defibrillation, atrial, 153
- defibrillator in acute myocardial infarction trial (DINAMIT), 204t, 205, 206, 208t, 209
- defibrillators, implantable. *See* implantable cardioverter-defibrillator (ICD)
- delayed afterdepolarizations (DADs), 193
- delta waves  
   anteroseptal bypass tracts, 231  
   multiple bypass tract  
     indication, 147
- depolarization, 6–7, 10–12, 23, 25, 26, 33, 40, 41, 51, 52, 79, 80, 197, 225  
   conduction velocity  
     association, 51  
   intracardiac recording, 37–8  
   spontaneous (*See also* automaticity)  
   surface ECG effects, 10
- device therapy. *See also specific devices*  
   reentrant arrhythmias
- diaphragmatic stimulation, 266, 267
- diastolic dysfunction, 304
- digitalis  
   agents, 26t, 27, 130  
   toxicity, 103  
   supraventricular  
     arrhythmia, 22
- digitoxin, 26t
- digoxin, 26t, 73
- diltiazem, 26
- direct current (DC)  
   cardioversion., 105
- direct current (DC) shock  
   inducible ventricular  
     tachyarrhythmias, 59  
   radiofrequency ablation  
     *versus*, 212  
   for transcatheter ablation, 211
- direct-current (DC) shocks for transcatheter ablation, 211
- disopyramide, 25, 26t, 30t, 31t, 281, 282
- dizziness, 72, 96, 167, 171, 285, 287, 292, 303, 304, 305t
- dofetilide, 26t, 27, 30t, 153
- dronedaron, 27, 30t, 31t
- dronedaronesotalol, 26t
- dysautonomias, 287, 289  
   cause, 288  
   drug therapy, 297  
     trusting doctor–patient  
       relationship, 298
- non-drug therapy  
   exercise, 296  
   fluid management and daily  
     precautions, 297  
   nonpharmacologic  
     measures, 297  
     underlying causes, 295–6
- objective findings, 289
- orthostatic symptoms, 297
- palpitations, 290–1
- syncope, 291–2
- tachycardia, 292–4
- treating, 294–5, 298  
   patience component, 295
- early afterdepolarizations (EADs), 190, 192f
- ECG. *See* electrocardiogram (ECG)
- echocardiograms, 283t, 284, 289, 302
- echocardiographic dyssynchrony study, 270

- echocardiography, 302
- effective refractory period  
(ERP), 53–5, 84, 86, 87, 114,  
123, 124, 136, 146, 175
- AV node, 54
- His-Purkinje, 84
- reentrant arrhythmias, 55
- supraventricular tachycardia  
initiation, 134
- electroanatomic mapping  
systems, 250–1, 256
- CARTO mapping system, 251–3
- comparison study, 256t–257t
- EnSite Array system, 254–5
- EnSite NavX system, 254
- electrocardiogram (ECG)
- abnormal sinus node recovery time  
(SNRT), 65f
- atrial flutter, 108f
- AV block localization, 275
- AV nodal reentry with atrial  
extrastimuli, 125f
- bundle branch reentrant  
tachycardia, 248
- cardiac action potential  
relationship, 11
- delta wave, 135f, 147
- with first-degree AV block, 81f
- from high right atrium (RA) during  
sinus rhythm, 40f
- intracardiac electrogram  
association, 40–41
- intra-ventricular conduction  
delay, 249
- 12-lead ECG, 105, 129
- patient with AV bypass  
tract, 133f
- localization of bypass tracts, 221
- measurement of sinoatrial  
conduction time, 70f
- normal VA conduction during right  
ventricular pacing, 116f
- PR interval, 4, 11, 14, 123, 135f,  
146
- P waves, 74, 151f, 157
- QRS complex, 10f, 49f, 90, 132,  
222
- QT interval prolongation, 193
- recording during reentrant  
arrhythmias, 56, 58
- signal-averaged, 277, 284
- ST segment elevation, 197
- supraventricular tachycardias,  
171
- surface ECG leads and right atrial  
(RA) electrogram, 65f, 70f
- syncope, 277, 282, 283
- electrode catheters, 38–9, 45
- baseline recording of intracardiac  
electrograms, 49f
- His-bundle electrogram, 47
- insertion and positioning, 45–8
- modified Seldinger technique, 45
- positioning  
in coronary sinus, 46f  
of the His-bundle catheter, 48f  
in right ventricle, 47
- quadripolar, 39, 251
- electroencephalography (EEG), 283,  
283t
- electromagnetic mapping, 238
- electrophysiologist, 298
- electrophysiologic properties of  
heart, 50
- automaticity, 50–51
- conduction velocity, 51–2
- refractory periods, 52–5
- electrophysiologic studies, 286, 301,  
308. *See also specific techniques/*  
*indications*
- arrhythmia evaluation/  
treatment, 55
- AV block, 275
- AV conduction disturbances, 84,  
128
- baseline recording, 47, 49f, 110f
- bypass tracts, 146
- complications, 59
- coupling interval, 38, 38f, 53, 70f,  
86f



- cycle length, 37–8
- electrode catheter, 38–9
- electrode catheters (*See* electrode catheters)
- intracardiac electrogram
  - recording, 40–41
- laboratory setup, 17, 21, 32, 38f, 42, 43, 53, 58, 102, 144, 161, 162, 182, 221, 301
- pacemaker selection, 101
- pacing, 41–2, 93
- patient preparation, 44–5
- performance of, 42
- protocol, 48–50
- recording, 37
- recording intracardiac
  - electrograms, 40–41
- reentrant supraventricular tachyarrhythmias, 109, 156
- reentrant ventricular arrhythmias, 164, 173, 187
- SA nodal dysfunction, 71
- sinoatrial conduction time, 67
- syncope, 177, 283t
- electrophysiologic testing, 276, 284, 299
  - complications of, 59
- electrophysiology laboratory, 301
  - physical setup of, 42–4, 43f
- empiric trial-and-error
  - therapeutic, 305
- encainide, 26t, 27, 199, 300
- EnSite Array system, 254–5
- EnSite NavX system, 254
- entrainment mapping, 245
- epicardial mapping, 213, 266, 267
- equipment, 42, 43, 44, 289
- ERP. *See* effective refractory period (ERP)
- escape pacemakers, 15f
- exercise-related syncope, 284
- extrastimulus pacing, 41, 42f
- false-positive response, 281
- fasciculoventricular bypass tracts, 147
- flecainide, 26t, 27, 30t, 31t, 143, 153, 199, 300
- fluoxetine, 281
- focal atrial tachycardias,
  - ablation, 233
- functional refractory period (FRP), 54, 55, 84, 86, 174, 180
- gastrointestinal symptoms, 297
- Gulf War syndrome, 288
- health maintenance goal, 305
- “Heart attack.” *See* myocardial infarction
- heart block. *See* atrioventricular (AV) block
- heart disease, 62, 91, 92, 105, 122, 150, 152, 162, 163t, 196, 276, 283t, 302, 303t, 305
- heart failure, 259, 262
  - cardiac resynchronization therapy
    - indication, 265
  - hospitalization rate, 264
  - implantable cardioverter-defibrillator indication, 202–4, 206
  - symptoms, 262
    - NYHA class, 264
- heart rate, 37, 60, 66, 70, 97, 188, 258, 293, 294, 296
- heart rhythms, abnormal. *See* arrhythmias
- Heart Rhythm Society, 265
- heart’s electrical system, 3–5, 4f
  - localized variations, 9
    - in action potential, 9–11, 9f
    - in autonomic innervation, 11
- His bundle
  - ablation, 214
    - direct current shock, 211
    - radiofrequency, 211–3
  - electrogram
    - AV conduction disorder
      - evaluation, 79

- His bundle (*Continued*)  
  conduction velocity  
    measurement, 51  
  electrode catheter  
    positioning, 46  
  split, 81, 82
- His-bundle electrogram, 51, 52
- His–Purkinje system, 4, 15, 49, 60  
  block, 115 (*See also* bundle branch block)  
  conduction time, 52  
  dysfunction, 87  
  effective refractory period, 88  
  Mobitz type II block, 83
- Holter monitor, 164, 169, 301
- H spike, 51, 79, 80, 83, 86f, 88, 91f, 115, 137f
- Huntington’s disease, 295
- HV interval, 52, 75f, 80, 81f, 83f, 88, 93, 147, 248  
  prolongation, 52, 84, 88
- ibutilide, 26t, 27, 30t, 153
- ICD. *See* implantable cardioverter-defibrillator (ICD)
- idiopathic left ventricular tachycardia, 163t, 195, 247, 248  
  ablation, 247
- implantable cardioverter-defibrillator (ICD)  
  Brugada syndrome, 197  
  high-risk patients, 200  
  patient selection, 33  
  randomized trial drawbacks, 208f  
  rationing, 209  
  ventricular arrhythmias  
    evidence-based approach, 202, 208f  
    indications for, 206–9  
    malignant tachycardia, 33  
    primary prevention trials, 202–6, 203t, 204t  
    reentrant, 163t, 164  
    secondary prevention trials, 202
- implantable rhythmmonitor, 302
- inappropriate sinus tachycardia (IST), 71, 104f, 287, 292, 304  
  cause, 293  
  electrophysiologist, 292  
  etiology, 104  
  heart-rate response, 293  
  orthostatic hypotension, 292  
  SA nodal ablation, 293  
  symptoms, 104, 292, 294, 304  
  treatment, 293, 294
- incremental (burst) pacing, 41  
  AV conduction disorders, 88  
  normal response, 88  
  reentrant supraventricular tachycardia, 181f  
  reentrant ventricular arrhythmia termination, 180, 181f
- intraatrial conduction interval, 52
- intraatrial reentrant supraventricular tachycardias, 150, 152
- intraatrial reentry, electrophysiologic study, 148–9
- intracardiac electrogram, 40  
  bypass tract mapping, 139  
  recording, 40, 40f, 49f  
  supraventricular tachycardia, 109  
  surface ECG association, 142f
- intraventricular conduction delay (IVCD), 90
- intrinsic heart rate (IHR), 70–71
- irritable bowel syndrome (IBS), 287
- ischemic heart disease  
  clinical trials using  
    amiodarone, 201t  
  ICD, 207, 209  
  reentrant ventricular arrhythmias, 162
- isoproterenol infusion, 121, 145, 176, 193, 196  
  right ventricular outflow tract tachycardia induction, 247  
  syncope, 281  
  tilt table testing for vasodepressor syncope, 281

- IST. *See* inappropriate sinus tachycardia (IST)
- Jervell-Lange-Nielson syndrome, 193
- Junctional escape (JE) pacemakers, 15f
- Koch's triangle, 216, 217f, 218f, 219f, 228, 230
- laboratory setup, 42
- laser energy, 213
- LBBB. *See* left bundle branch block (LBBB)
- left atrial to left ventricular (LA-LV), 269
- left bundle branch block (LBBB), 92-3, 260
- left free wall bypass tract ablation, 226
- left posteroseptal tachycardia. *See* idiopathic left ventricular tachycardia
- lidocaine, 25, 26t, 27, 30, 189
- lightheadedness, 62, 63, 72, 171, 182, 190, 279, 303 305t
- macroreentrant supraventricular tachycardias. *See* supraventricular tachycardias, macroreentrant
- macroreentrant tachycardia  
atrial preexcitation, 142f  
relationship of P to QRS during, 141, 143f  
supraventricular tachycardia, 141  
treatment, 141, 143
- MADIT-CRT trial, 265
- magnesium sulfate, 193
- magnetic field mapping. *See* CARTO mapping system
- magnetic resonance imaging (MRI), 253, 254, 256t, 270
- Mahaim bypass tracts, 146-7, 227-9
- malignant ventricular tachycardia, 20, 29, 33
- mapping  
AV nodal reentrant tachycardia ablation, 214  
bypass tracts, 223  
reentrant ventricular tachycardia, 242
- "Maze" procedure, 236
- mechanocardiac receptors, 279
- mexiletine, 25, 26t, 30t
- microwave energy, 213
- midseptal bypass tract ablation, 231, 232f
- mitral valve prolapse (MVP), 131, 287  
ventricular arrhythmia association, 198
- mobile cardiac outpatient telemetry, 302
- Mobitz type I block (Wenckebach block), 74, 78, 82, 88  
His bundle electrogram, 75f  
incremental pacing, 88
- Mobitz type II block, 74, 83f  
His bundle electrogram, 83f  
location, 83
- modified Seldinger technique, for positioning of electrode catheters, 45
- moricizine, 26t, 30t, 199
- MOST trial, 271
- multicenter autonomic defibrillation implantation trial (MADIT I), 203, 204t, 205, 207, 208, 209
- multicenter autonomic defibrillation implantation trial (MADIT II), 204t, 205, 207, 208t, 209
- multicenter unsustained tachycardia trial (MUSTT), 204t, 205, 207-9
- multifocal atrial tachycardia, 17, 104f
- MVP syndrome, 289

- myocardial contraction, electrical  
impulses of, 5
- myocardial fibrosis, 73, 164, 276
- myocardial infarction  
automatic ventricular  
arrhythmias, 163t, 189
- implantable cardioverter-  
defibrillator, indication, 206
- proarrhythmic effect of  
antiarrhythmics, 199
- reentrant ventricular  
arrhythmias, 162, 163t, 164,  
166
- transmural, 11, 236
- Narula method, 70
- neurasthenia, 285, 286
- neurasthenics, 287
- noncontact mapping, 238, 254, 255
- nuclear angiography, 302
- NYHA class, 264
- outflow tract ventricular  
tachycardia, 163t, 195
- overdrive suppression, 50  
automaticity, 50  
SA node, 61–2  
sinus node recovery time, 63–6,  
65f  
supraventricular tachycardia and  
syncope, 275
- pacemaker cells, subsidiary, 13, 14,  
15f, 50, 76
- pacemakers (artificial). *See also*  
cardiac resynchronization  
therapy (CRT); pacing;  
permanent pacemakers  
AAI, 94–6, 101  
AAIR, 96, 101  
atrial fibrillation, 96, 151f  
DDD, 94, 96, 97f, 98, 99  
DDDR, 98, 101, 271  
dual-chambered, 94, 98, 100, 101,  
258, 271  
nomenclature, 94  
pacing modes, 94, 96, 265, 271  
selection of, 100  
single-chambered, 94, 95, 96,  
101  
tachycardia, 98, 99f  
VVI, 94, 95, 98  
VVIR, 96, 98, 101
- pacemaker syndrome, 96, 100, 278t
- pace-mapping, 240
- pacing. *See* cardiac resynchronization  
therapy (CRT); pacemakers  
(artificial)
- palpitations, 167, 171, 182, 275, 285,  
290, 292. *See also*  
dysautonomias
- paraseptal bypass tract ablation, 229,  
229f, 230
- parasympathetic tone, 11, 55, 61,  
118
- paroxysmal atrial tachycardia  
(PAT), 105–7, 156, 158, 171
- patient preparation, 44–5
- pause-dependent triggered activity  
ventricular arrhythmias,  
163t, 190, 193, 194f
- PAVE trial, 271
- permanent pacemakers, 93  
indications, 93  
AV conduction disease, 93  
cardiac resynchronization  
therapy, 93  
symptomatic sinus  
bradycardia, 93  
syncope, 93
- modes of pacing, 94  
CRT pacing, 99–100  
DDD pacing, 96–8  
VVI or AAI pacing, 95–6
- nomenclature, 94  
selection, 100–101, 100f  
electrophysiology study helpful  
in, 101
- phenytoin, 25, 26t, 30t, 31t, 189
- physiologic recorder, 44

- plateau phase of action potential, 7
- posterior septal bypass tract
  - ablation, 229
- post-traumatic stress disorder (PTSD), 287
- postural orthostatic tachycardia syndrome (POTS), 287
- post-ventricular atrial refractory period (PVARP), 98
- premature beat/impulse
  - extrastimulus pacing, 42
  - pacing, induction by, 148
- premature ventricular (PV)
  - complexes, 65f, 98, 162, 163, 192, 194f, 255, 303t
- PR interval
  - action potential, 9–10
  - AV conduction, 80
  - AV nodal bypass tracts, 146
  - AV nodal reentrant tachycardia, 122f
  - bypass tract-mediated macroreentry, 135
  - conduction velocity, 52
  - heart block, 14f
  - intracardiac electrograms, 49f
  - Mobitz I AV block, 75f, 82f
  - Mobitz II AV block, 75f
  - supraventricular tachycardia, 157f
- proarrhythmia, 29–30, 153, 199, 300
- procainamide, 25, 26t, 30t, 31t, 183f
- programmed stimulation, 41
- propafenone, 26t, 27, 30t, 143, 153
- pulmonary veins, 96, 156, 233, 238, 239, 251, 253
- Purkinje fibers, 5, 89, 115, 132, 147
  - depolarizations, 51
- P wave, 46, 52
  - action potential, 11
  - atrial fibrillation, 149
  - atrial flutter, 149
  - AV block, 74, 75f, 76f
  - AV dissociation without complete heart block, 77f
  - AV nodal reentry, 125f, 129
  - incremental atrial pacing, 89
  - intraatrial reentry, 107, 148
  - intracardiac electrograms, 49
  - macroreentrant tachycardia, 141, 143f
  - Mobitz I AV block, 82f
  - Mobitz II AV block, 75f
  - multifocal atrial tachycardia, 104
  - SA nodal reentry, 107, 149
  - supraventricular tachyarrhythmias, 103, 156, 157f
- QRS complex, 52, 55, 259
  - AV nodal bypass tracts, 146
  - AV nodal reentrant tachycardia, 125
  - delta wave, 132
  - distal conducting system disease, 78
  - ECG, surface, 10f
  - electrophysiology study, 248
  - pacemaker, 95
  - P waves, 74, 103, 128, 129, 148, 157
  - randomized trials with CRT, 263t
  - sinus P waves, 107
  - VA interval, 97
  - ventricular tachycardia, 168
  - wave of depolarization, 11
- QT interval, 10, 12, 30, 190, 191, 193, 195, 197
- QT syndromes, 277
  - prolongation, 193
- quadripolar electrode catheter, 39
- quinidine, 25, 26t, 30t, 31t, 183f, 194f
- Q waves, 133, 282
- RACE trial, 154
- radiofrequency ablation, 146
  - complications, 255, 257
- radiofrequency (RF) energy, 149, 159, 211–2
- disadvantages, 212

- RBBB. *See* right bundle branch block (RBBB)
- recording, 37, 40–41
- reentrant arrhythmias. *See also specific types*
- effect of antiarrhythmic drugs, 58–9
  - effect of autonomic maneuvers, 58–9
  - effect of devices on, 58–9
  - effect of premature impulses on, 57f
  - evaluation of, 55
  - programmed stimulation, 55–6
  - recording electrograms during, 56, 58
- reentrant supraventricular tachycardias, 105, 106f
- AV nodal reentrant tachycardia, 106
- bypass tracts, 134
  - mechanism of, 134
  - pacing techniques, 121
  - SA nodal, 196
  - treatment of, 141
- reentrant ventricular tachycardia, 171, 184, 196, 243f
- ablation of, 239
  - method for mapping, 242
  - ventricular muscle, 240
- reflex syncope, 278. *See* vasodepressor syncope
- refractory period, 52–5
- repolarization, 7
- resting phase, 8–9, 8f
- retrograde conduction, reentrant tachycardia, 147
- reverse modeling, cardiac resynchronization therapy, 262
- right bundle branch block (RBBB), 91–2
- right ventricular dysplasia, 196
- Romano-Ward syndrome, 193
- SA. *See* entries beginning sinoatrial (SA)
- SACT. *See* sinoatrial conduction time (SACT)
- Seldinger technique, modified, 45
- serial drug testing
- antiarrhythmic drugs, 207
  - antiarrhythmic drug therapy, 199
  - electrophysiologists, 162
  - in electrophysiology laboratory, 58
  - inducibility/noninducibility, 183
  - pharmacologic therapy, 182
  - successful, 182, 183f, 185
  - for ventricular arrhythmias, 161
- severe cardiomyopathy, 307
- Shy-Drager syndrome, 295
- sick sinus syndrome, 13
- signal-averaged ECG, 277
- signal-averaged surface ECG
- reentrant ventricular arrhythmias, 166
- sinoatrial conduction time (SACT), 67–70
- sinoatrial (SA) node, 3
- ablation, 149
  - action potential, 8, 10
  - anatomy, 61
  - automaticity (*See also* sinus node recovery time (SNRT))
  - assessment, 48, 50
  - disordered, 63
  - insufficiency, 13
  - autonomic innervation, 11
  - conduction time (*See* sinoatrial conduction time (SACT))
  - disease, guidelines for
    - assessment, 71–2  - dysfunction, 61
    - assessment guidelines, 71
    - pacemaker selection, 100  - electrophysiologic evaluation
    - indications for, 62, 63, 68f, 72  - exit block, 61, 67, 68
  - fibrosis, 62

- inappropriate sinus tachycardia
  - (*See* inappropriate sinus tachycardia (IST))
- intrinsic heart rate, 70, 293
- normal sinus rhythm
  - generation, 8, 40, 148
- overdrive suppression, 50, 63, 65, 66
- reentry, electrophysiologic study
  - in, 149
- sinus bradycardia, 290
- sinus nodal dysfunction, 275, 303t
- sinus node recovery time (SNRT), 63–7
- sinus rhythm
  - AV nodal reentrant tachycardia, 219
  - His deflection, 248
  - left bundle branch block (LBBB), 228
- sinus tachycardia, 290. *See also*
  - inappropriate sinus tachycardia (IST)
- SNRT. *See* sinus node recovery time (SNRT)
- sodium channels
  - cardiac, 197
  - in cell membrane, 6
  - effect of class I drugs, 24
  - genetic abnormalities, 197
  - SA and AV nodal tissues, 10
- sodium consumption, 297
- sodium ions, 6, 7, 23, 24f
- sotalol, 27, 30t, 31t, 203t
- Strauss method, 70
- ST segment, 10, 12, 197
- sudden cardiac death in heart
  - failure trial (SCD-HeFT), 205–7
- sudden death, 30, 33, 160, 161, 165, 170, 189, 197, 200, 206, 276, 300, 305, 308
  - arrhythmia recurrence, 170
  - cases of, 214
  - intensive care unit, 189
  - risk of, 165, 198, 308
  - stress-induced, 197
  - survivors, 169, 170
  - typical sequence of events, 170f
- sudden unexpected nocturnal death syndrome (SUNDS), 197
- supraventricular tachyarrhythmias,
  - reentrant, 105
  - activation, 113
  - atrial flutter/atrial fibrillation, 107–9
  - autonomic maneuvers, 118
  - AV conduction curve, 114f
  - AV nodal reentrant tachycardia, 106f
    - electrophysiology study, 121–2
    - evidence, 128–9
    - initiation and termination, 124–6, 125f, 126f
    - mechanism of AV nodal reentry, 122–3
    - observations, 129
    - patterns of activation, 127–8
    - treatment, 130
    - typical AV conduction curve, 127f
  - baseline recordings, 110f
  - bundle branch block, 119
  - bypass tract-mediated macroreentrant tachycardia, 106–7
  - drugs effect on, 118
  - electrophysiology study, 109
  - evaluation, 111, 156–9
  - initiation, 111–3
  - intraatrial reentry, 107
  - patterns, 117
  - positioning catheters, 109–11
  - procedure, 119–21
  - P wave, 157f
  - reentrant circuit, 117
  - SA nodal reentry, 107
  - termination, 111–3

- supraventricular tachycardias, 20,  
45, 102, 130  
antegrade activation, 113  
automatic, 103  
autonomic maneuver effect, 111  
baseline recording, 110f  
bypass tract-mediated, 105–6,  
130–5  
atrial/ventricular activation  
patterns, 139  
AV conduction curve, 140f  
electrophysiologic study, 130–  
4  
localization of, 143–4  
P wave, 141  
types, 135f  
classification, 103  
electrode catheter  
positioning, 119, 144, 174  
intracardiac recording of, 37  
macroreentrant, 135–42  
atrial preexcitation, 142f  
atria/ventricle requirement  
in, 140–1  
induction, 137f  
initiation, 135–6  
mechanism of, 134–5  
P wave QRS complex  
relationship in, 141  
termination, 135  
treatment, 141, 143  
pacing during, 135, 138, 139, 142f  
reentrant (*See* reentrant  
supraventricular tachycardias)  
reentrant circuits, 121  
retrograde activation, 139, 140  
syncope caused by, 275  
termination, 135, 139  
surface ECG. *See* electrocardiogram  
(ECG)  
sympathetic tone  
AV node, disproportionate  
effect, 55  
opposite effect, 11  
withdrawal of, 281  
symptom relief, 297, 307  
syncope  
arrhythmia-induced, 302  
AV nodal disease, 275  
bradyarrhythmias, 274  
causes of, 273  
electrophysiologic testing, use  
of, 170  
evaluation of (*See* Syncope,  
evaluation)  
treating vasodepressor, 281  
vasodepressor, syndromes of, 277,  
278, 279  
ventricular tachyarrhythmias, 276  
syncope, evaluation, 273  
bradyarrhythmias, causes of  
AV block, 275  
sinus nodal dysfunction, 274–5  
causes of, 273–4, 274t  
patient, evaluation, 282–4, 283t  
tachyarrhythmias  
supraventricular  
tachycardias, 275–6  
ventricular  
tachyarrhythmias, 276–7  
vasodepressor syncope, 277–82  
tilt-table testing, 280–1  
treating vasodepressor  
syncope, 281–2  
ventricular tachyarrhythmias, 276  
systemic embolization, pulmonary  
vein isolation risk, 239  
systolic dysfunction, 259  
systolic heart failure, 271. *See also*  
Heart failure  
tachyarrhythmias. *See* cardiac  
arrhythmias; tachycardias  
tachycardias. *See also specific types*  
automatic, 16–17  
antiarrhythmic drugs, 17  
electrophysiologic study in, 17  
pacemakers for, 16  
pacemakers, 41  
reentry, 17



- prerequisites for, 18f
- termination of, 20f
- right ventricular outflow tract
  - ablation, 196, 247
- sinus (*See also* inappropriate sinus tachycardia (IST))
- syncope cause, 62
- triggered activity, 21–2, 22f
- tachycardia zone, 27
- theophylline preparations, 281
- therapeutic endpoints, 300, 305, 307, 308
- tilt table testing, 280, 281, 283, 284, 291
- tissue Doppler echocardiography (TDE), 270
- tocainide, 25, 26t, 31t
- Torsades de pointes, 30
- transcatheter ablation, 210
  - atrial flutter, 151
  - AV junction, 213–4
  - AV nodal reentry, 130, 218f
    - tachycardia, 214, 216–20
  - bundle branch reentry, 196
  - direct current shocks, 211
  - intraatrial reentry, 148
  - macroreentrant supraventricular tachycardia, 134, 141
  - mapping methods, 223–5, 241
  - principles of, 210
  - radiofrequency energy, 211–3
  - right ventricular dysplasia, 196
  - success of, 243f
  - technology of, 210–1
  - ventricular tachycardia
    - outflow tract, 195–6, 247
- transesophageal
  - echocardiography, 153
- transmembrane potential, 5–8, 192
- transmural myocardial infarction, 11
- treatment plan design, 300, 306
- trial-and-error (empiric)
  - methods, 308
- triggered activity
  - catechol-dependent, 193, 195
    - treatment of, 195
  - clinical significance, 22
  - electrophysiologists, 21
  - pause-dependent, 190, 191f, 194f
  - ventricular arrhythmias, 22
    - ventricular arrhythmias, mechanisms, 163t, 190
- TU wave, 192, 193
- Twave, 10, 12, 157, 168, 169, 191, 240
- U wave, 191–4
- VA conduction, normal, 116
- vagal maneuvers. *See also* autonomic maneuvers
- vasodepressor syncope, 277, 278, 279, 280, 282, 287, 291, 292
  - syndromes of, 278t
    - tilt table testing, 280, 281, 283, 284, 291
- vasovagal syncope, 277, 278, 297. *See* Vasodepressor syncope
- V deflection, 52
- ventricles. *See entries beginning ventricular*
- ventricular arrhythmias, 276, 277. *See also specific types*
  - automatic, 189–90
  - Brugada syndrome, 197
  - bundle branch reentry, 196
  - evaluation, 162
  - idiopathic left ventricular tachycardia, 195
  - mechanisms of, 162, 163t
  - mitral valve prolapse
    - association, 198
  - outflow tract ventricular tachycardia, 195–6
  - right ventricular dysplasia, 196
  - serial drug testing, 198–200
  - sudden death and, 166t
  - sudden unexpected nocturnal death syndrome, 197
  - treatment

- ventricular arrhythmias (*Continued*)  
  electrophysiology study  
    in, 187–8  
  triggered activity, 190  
    catechol-dependent, 193  
    pause-dependent, 190, 194f
- ventricular dyssynchrony, 91, 92,  
  259, 260, 260f, 265, 270, 271.  
  *See also* cardiac  
  resynchronization therapy  
  (CRT)
- ventricular ectopy, 29, 164  
  antiarrhythmic drug effects, 198–9  
    amiodarone, 199–200, 201t  
    proarrhythmic effects, 199  
    serial drug testing, 199  
  complex, treatment, 300  
  reentrant ventricular  
    arrhythmias, 59, 162, 163t,  
    164, 166, 189, 239, 246
- ventricular fibrillation, 169f, 303  
  localization, 240  
  reentrant ventricular  
    arrhythmias, 162, 164, 166,  
    189  
  sudden death, 303  
  triggered by, 197
- ventricular function, 260f
- ventricular myocardium, 276
- ventricular pacing, 49  
  AV nodal reentry initiation, 126  
  electrode catheter  
    positioning, 175, 176  
  reentrant supraventricular  
    tachycardia, 121
- ventricular systolic function, 260, 262
- ventricular tachyarrhythmias, 276
- ventricular tachycardia, 168f, 276  
  ablation, 200, 239, 247  
  bigeminy, 194f  
  catecholamine-dependent, 58  
  degeneration, 181  
  dunk-tank model of, 186  
  figure-of-eight model, 242, 243t  
  idiopathic left, 163t, 195, 247–8  
  implantable cardioverter-  
    defibrillator, 33, 182, 204f,  
    208f  
  inducible, 59, 170, 175t, 178, 184,  
    188, 204t, 209  
  outflow tract, 195  
  pace-termination, 181f  
  polymorphic, 190  
    catecholaminergic, 197  
  reentrant, *See* reentrant ventricular  
    tachycardia  
  repetitive monomorphic, 195, 247  
  serial drug testing, 183  
  syncope caused by, 275–6
- verapamil, 26t, 104, 146, 158, 172,  
  223, 247
- V spike, 48, 79, 83, 88, 125
- V-V interval, 269
- VVI pacemakers, 95, 96
- VVIR pacemakers, 96, 101
- Wenckebach block. *See* Mobitz type I  
  block (Wenckebach block)
- Wenckebach conduction, 128, 130,  
  131, 141  
  AV nodal reentry, 128, 130  
  macroreentrant supraventricular  
    tachycardia, 130–1, 141  
  retrograde, 128
- Wenckebach cycle length, 88, 89,  
  124
- Wolff-Parkinson-White  
  syndrome, 106, 132, 303t